Molecular and biologic consequences of pharmacologic inhibition of TAK1 in lymphoma cell lines using AZ-TAK1. (A) Cell lines of Hodgkin lymphoma origin (HD), MCL, or anaplastic large cell lymphoma (ALCL) were incubated with increasing concentrations (0.1, 0.5, 1, and 2μM) of the AZ-TAK1 for 72 hours before cell viability was determined with the MTS assay. PBMCs from 3 healthy donors were included for comparison. Each value is the mean of 3 independent experiments performed in triplicate (± SEM). (B) IC₅₀ values for AZ-TAK1 in lymphoma cell lines and PBMCs at 72 hours (C) Effect of AZ-TAK1 on induction of apoptosis. The MCL cell lines Jeko-1, Mino, and SP53 were incubated with dimethyl sulfoxide (DMSO; 0.1%) or AZ-TAK1 (0.1 or 0.5μM) for 48 hours before apoptosis was measured using the annexin V/PI dual staining method and FACS analysis. (D) Summary results of AZ-TAK1–induced cell death (PI and annexin V–positive cells) from 3 independent experiments. Each value is the mean of 3 independent experiments performed in triplicate (± SEM). **P < .005. (E) Effect of AZ-TAK1 on cell-cycle analysis. The MCL cell lines Jeko-1, Mino and SP53 were incubated with DMSO (0.1%) or AZ-TAK1 (0.1 or 0.5μM) for 24 hours before cell-cycle analysis was performed using the PI staining method by FACS analysis.